Teva, Ivax Move Closer To Marketing Generic Gabapentin
Executive Summary
Teva and Ivax are moving into position to consider "at risk" launches of generic gabapentin (Pfizer's Neurontin)
You may also be interested in...
“Authorized” Generics Are “Legitimate Business Strategy,” Pfizer Says
Pfizer views "authorized" generics as a sound business strategy following a drug's patent expiration, Senior Corporate Counsel Jeffrey Chasnow said during a Drug & Device Dialogue audio conference Oct. 7
“Authorized” Generics Are “Legitimate Business Strategy,” Pfizer Says
Pfizer views "authorized" generics as a sound business strategy following a drug's patent expiration, Senior Corporate Counsel Jeffrey Chasnow said during a Drug & Device Dialogue audio conference Oct. 7
Ivax Launches Neurontin Generic “At Risk” As Pregabalin User Fee Date Nears
Ivax' "at risk" launch of generic gabapentin comes less than two weeks before the anticipated FDA user fee date for Pfizer's Neurontin follow-on drug Lyrica